

CLEAR SKY
RECOVERY

A Universal Ibogaine brand

**CREATING THE GOLD STANDARD FOR
ADDICTION TREATMENT WITH
IBOGAINE-ASSISTED PSYCHOTHERAPY**

September 14, 2020

FORWARD-LOOKING STATEMENTS

This presentation is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to assist the recipient in evaluating Universal Ibogaine (“UI” or the “Company”). The presentation is not, nor is it construed under any circumstances as a prospectus, a public offering of securities, or an offering memorandum as defined under any applicable securities legislation. The presentation does not contain all of the information that would normally appear in an offering registered under applicable securities laws.

The information contained herein is subject to change without notice and is based on publicly available information, internally developed information and other sources. Where any opinion or belief is expressed herein, it is based on assumptions and limitations mentioned and is an expression of current opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature, arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. The information contained in this presentation is not directed to person or entities resident in the United States and does not constitute an offer or a solicitation by anyone in the United States (“U.S.”) or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation.

ANY SECURITIES DESCRIBED IN THIS PRESENTATION HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATES OF THE U.S.

THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO “U.S. PERSONS” AS SUCH TERM IS DEFINED IN THE REGULATIONS UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.

Certain statements contained or incorporated in this presentation, which deal with the financial condition and results of the Company, include information, projections and analyses as to future corporate developments which are currently in the planning stage and reflect the current expectations of the Company’s management regarding future growth, results of operations, performance, business prospects and opportunities. Such forward – looking statements, made with special reference to the Company’s technology and treatment protocol and medical research and developments efforts, which may include in-house and independent pre-clinical and clinical trials involve known and unknown risks and uncertainties that could cause actual events and/or results to differ materially from those estimated and/or anticipated and which may have been implied and/or expressed in such forward-looking statements. No conclusions as to the successful outcome of the ongoing and planned R&D projects in which the Company is or will be involved, are intended or implied nor can they be foreseen or predicted prior to definitive corporate announcements as to their outcome.

CLEAR SKY RECOVERY

Building a network of holistic recovery clinics focusing on the scientific application of ibogaine to treat the roots of addiction

**Born of Holistic Healing
Backed By Science**



OUR MISSION, VISION AND VALUE PROPOSITION

MISSION

To treat the roots of addiction effectively using ibogaine and other psychedelic medicines

VISION

Creating the gold standard for addiction treatment with ibogaine-assisted psychotherapy

VALUE PROPOSITION

To provide those living with addiction the best possible recovery treatment - using ibogaine and other psychedelic medicines - to enable them to be free from addiction and to flourish

THE PROBLEM: ADDICTION IS THE EPICENTRE OF THE MENTAL HEALTH CRISIS

2 hours

The average time that passes between deaths in Canada by illicit drug overdose

1 in 5

The number of Canadians who suffer from addiction in any given year

50%

of Canadians will be affected by mental health issues by the age of 40 (many of these will have addiction issues)

93%

increase in overdose deaths amongst First Nations communities in BC (2019-2020)

- An acute opioid crisis
- Part of an expanding addiction crisis
- Propelled by a widespread mental health crisis

Source: Overdose by Benjamin Perrin, 2020; Center for Addiction & Mental Health (CAMH)



DRUG ADDICTION: A KEY PART OF THE MENTAL HEALTH CRISIS

Typical treatments are temporary

Low effectiveness and high relapse rates

Current reliance on substitution therapies, with addictive properties

Lifelong recovery is possible.

Psychedelic medicinal alternatives and therapeutic healing modalities make recovery enduring and sustainable

Example: Suboxone

>90% failure rate



Rate of unsuccessful outcomes
(after Suboxone taper after a 12-week treatment)

**“If we’re just substituting one opioid for another,
we’re not moving the dial much”**


— Tom Price, Former U.S. Secretary of HHS



THE OPPORTUNITY OF PSYCHEDELIC MEDICINE



Valuations and Capital raised (\$m)



Widespread acknowledgement that psychedelics enhance treatment approaches to:

- opioid addiction
- mental illness
- spiritual development

Increasing awareness of psychedelics as an alternative to traditional medicinal approaches

Increased investment fueling the “next generation” of psychedelic medicines

IBOGAINE: MEDIUM-LONG TERM

THE BENEFITS OF IBOGAINE


- Ibogaine is a naturally-occurring molecule originally derived from the root bark of a shrub found in the Congo Basin
- The most powerful addiction-interrupting psychedelic on the planet
- Regulates dopamine reuptake and many other neurotransmitter systems
- Metabolizes into noribogaine, a serotonin reuptake inhibitor that remains in the body for 1-4 months, eliminating addictive cravings
- Will medicalise globally this decade, starting in Canada (currently on the Prescription Drug List)



IBOGAINE SAFETY


AN IMPECCABLE TRACK RECORD


- Clear Sky Cancun was founded in 2003 and has treated over 3,500 patients successfully to date
- Our licensing agreement with Clear Sky Cancun gives us exclusive rights to their safety protocol
- Dr Alberto Sola has treated more people with ibogaine than anyone else in the world and sits on the Universal Ibogaine board
- Clear Sky Cancun patient data will be used in preparation for the Clinical Trial Application
- Clear Sky Cancun's record demonstrates that ibogaine is **100% safe** if used in a medical setting



HOLISTIC RECOVERY CLINICS: NEAR TERM IN CANADA

- Residential suburban/rural recovery centres
- Innovative non-psychedelic detox methods
- Residential aftercare following on from ibogaine treatment
- Holistic treatment programmes
- Revenue in year 1





IBOGAINE CLINICAL TRIALS

Our planned clinical trials in Canada:

- Should confirm and extend the Clear Sky Cancun data (3,500 patients treated to date) and treatment protocol
- Are intended to be the basis for legitimizing its medical use in Canada, the US and other markets
- Will be led by a distinguished medical team and Clinical Research Organisation support
- Begins with Phase I: safety data in healthy adults

Eight-year data protection period in Canada for innovative drugs

OUR PATHWAY TO IBOGAINES

Universal Ibogaine
(Public Holding Company)



Clear Sky Recovery
(Brand and IP Ownership)



TRACK 1: Clear Sky Recovery
Holistic Psychotherapy
Retreats in Canada & US

- Holistic treatment modalities - meditation, counselling, yoga, nutrition, breathwork, IV drips etc.
- Psychedelic-assisted where regulated

TRACK 2: Clear Sky Recovery
Holistic Psychotherapy
Retreats overseas
IBOGAINE

- Ibogaine retreats in legal jurisdictions globally, supported by digitally-assisted intake process

FROM PRIVATE TO PUBLIC

Why go public now? To enable public participation in an ibogaine-focused company incorporating:

- Clinical trials for ibogaine in Canada
- Psychedelic-assisted therapy where legal
- Significant commercial opportunities in other jurisdictions

How?

- Q4 2020 Go public event - RTO with P Squared Renewables




WHY CANADA FIRST?


North American market entrance for Ibogaine use through Canada is driven by THREE impetus points

Canadian clinical trials will prime the Clear Sky brand for acceptance in Canada and potentially for penetration into lucrative US & other markets

Faster potential runway to commercialization than the USA



Relatively receptive market (cf, legalization of cannabis)



OUR ADDRESSABLE CANADIAN MARKET

Not just “junkies”...

1 in 5

Canadians live with
addiction each year


“This is not ‘those addicts’ - this is your brother, your uncle, your sister, your mother, and father. You think about why people use street drugs and a lot of it has to do with pain, whether it’s psychological, emotional, or physical pain that gets people into it”

— Dr. Bonnie Henry, BC Chief Medical Officer,
from *Overdose: Heartbreak and Hope in
Canada’s Opioid Crisis*. P.31

Source: *Overdose* by Benjamin Perrin, 2020; Center for Addiction & Mental Health (CAMH)



ADDRESSABLE CANADIAN ADDICTION MARKET IS GROWING



Source: Canadian Alcohol and Drug Use Monitoring Survey, 2012



ADDRESSABLE CANADIAN ADDICTION MARKET: **IBOGAINE**

Immediate Addressable Market (Based On Household Income)	750,000	
Estimated Market Penetration (Per Clinic)	0.05%	
Patient Count	Per Annum	375
	Per Month	31
	Per Week	8
Price Per Treatment (7 Day Program)	CAD \$20,400	
Annual Revenues (Per Clinic)	CAD \$8.7M*	

* Based on Clear Sky Cancun fee structure and 75% occupancy


ADDRESSABLE CANADIAN ADDICTION MARKET: **HOLISTIC RECOVERY**

Clinic Treatment Capacity	12 Beds	
Price Per Stay	CAD \$20,300 (weekly) \$40,500 (monthly)	
Weekly Vs. Monthly Ratio	50%	
Annual Revenues (Per Clinic)	2021 @40% Occupancy	CAD \$3.7M
	2025 @70% Occupancy	CAD \$6.9M

OUR COMPETITIVE EDGE

Clear Sky Recovery: the leading brand combining the best of available addiction know-how with medicalized ibogaine

- Sunshine Coast HC
- GreenStone
- Canadian Centre for Addictions
- Ledgehill



- Atai/Compass Pathways
- Gilgamesh
- MindMed

- Wholeness Clinic
- Field Trip
- Native Healing
- Numinus

DIGITAL SUPPORT

PHASE 1 of Clear Sky Recovery App/Website

Digital Platform generates operational efficiencies:

- Ibogaine therapy information provision
- Intake funnel (exclusion criteria, application form, informed consent)
- Pre-treatment preparation
- Booking & billing
- After-care support



OPERATIONAL BUILD OUT

2020

- First Clinic Acquisition (Kelburn)
- Phase 1 & 2 Clinical Trials Approval
- Digital Platform build-out
- Set up not-for-profit

2022

- 3 Clear Sky Recovery Retreats (total in Canada)
- 2 Clear Sky Recovery Retreats (ibogaine overseas)

2024

- 9 Clear Sky Recovery Retreats (total in Canada)
- 2 Clear Sky Recovery Retreats (ibogaine overseas)

2021

- 2 Clear Sky Recovery Retreats (ibogaine overseas)
- Phase 3 Clinical Trials Approval

2023

- 6 Clear Sky Recovery Retreats (total in Canada)
- 2 Clear Sky Recovery Retreats (ibogaine overseas)

2025

- 12 Clear Sky Recovery Retreats (total in Canada)
- 2 Clear Sky Recovery Retreats (ibogaine overseas)
- Phase 3 Conclusion & Ibogaine Roll-Out

BUSINESS MODEL

Clear Sky Recovery (a wholly owned subsidiary of Universal Ibogaine) will derive income from:

- Owned and franchised non-psychedelic retreats in Canada and overseas jurisdictions where ibogaine is legal

BELIZE

Universal Ibogaine holds a 20 acre land parcel in Belize. In negotiations with a European resort developer for the formation of a JV partnership to finance and develop a resort.

OUR FINANCIAL PROJECTIONS (\$ CAD MILLIONS)

	2020	2021	2022	2023	2024	2025
Total # Clinics	1	3	5	8	11	14
Revenues	-	16.0	29.2	51.7	79.7	106.2
Net Operating Income	(0.8)	6.7	13.2	24.4	38.8	52.4
G & A Expenses	0.8	4.6	6.8	10.0	12.7	16.0
Net Income Before Tax	(1.6)	2.1	6.3	14.4	26.1	36.4
Capex	1.8	15.5	7.0	10.5	10.5	10.5

CAPITAL RAISE & PROPOSED USE OF FUNDS (\$ CAD)

	Private Raise	Prospectus Financing	Total
Unit Offering - # of common shares	8,000,000	20,000,000	28,000,000
Raise Proceeds - maximum	\$2,000,000	\$5,000,000	\$7,000,000
Brokerage, legal & other costs	(100,000)	(650,000)	(750,000)
Total Intended Use of Net Proceeds	\$1,900,000	\$4,350,000	\$6,250,000

Acquisition of initial clinic		950,000	950,000
Clinical Trials Phase 1 & 2	100,000	2,900,000	3,000,000
Working Capital	1,800,000	500,000	2,300,000
	1,900,000	4,350,000	6,250,000

UI is undertaking a private placement (\$2 million of \$0.25 Units) and plans an RTO amalgamation with P Squared Renewables ("PSQ" a TSXV listed company) by way of a Prospectus offering (up to \$5 million) in fall 2020.

CAPITAL STRUCTURE

# millions of shares	Per Share	UI	PSQ	TOTAL
Shares issued and outstanding		54.4	11.5	65.9
Issuable on closing Clear Sky Licensing		30.0		30.0
Issuable on closing Belize		25.0		25.0
Issuable on Liquidity Event		8.9		8.9
		118.3	11.5	129.8
Current UI unit Financing (maximum)	\$0.25	8.0		8.0
Proposed IPO unit Financing (maximum)	\$0.25		20.0	20.0
Proposed acquisition of Kelburn clinic	\$0.25		2.0	2.0
Proforma total on closing of Prospectus Financing		126.3	33.5	159.8

The above shows the estimated Pro Forma totals for common shares expected to be outstanding following closing of UI's current financing & the RTO transaction with PSQ

CAPITAL STRUCTURE - ADDITIONAL SHARES RESERVED FOR ISSUE

# millions of shares	Per Share	UI	PSQ	TOTAL
Broker options/warrants	\$0.10	3.8		3.8
Performance shares - director's time based vesting	\$0.10	2.3		2.3
Stock options	\$0.10		0.9	0.9
Warrants - units & prospectus financing		8.0	11.0	19.0
Broker warrants - prospectus financing (2 year term)	\$0.25		2.0	2.0
Totals on closing of prospectus financing*		14.1	13.9	28.0

* Directors & Officer shareholdings are approx. 8.0% of UI current, and will be 16.7% of estimated Pro Forma total outstanding

** Warrants to have a term of 5 years, with exercise price escalating by \$0.25 per year, starting at \$0.50 if exercised in year 1.

OUR LEADERSHIP TEAM



Dr. Jeremy Weate - CEO and Director

Jeremy has over 17 years strategic advisory experience, focused on minister-level guidance on the mining sector across over 50 projects in over 30 countries in Europe, Africa, Central Asia and the South Pacific. Jeremy also has a decade-long interest in the medicalization of ibogaine in a holistic treatment setting. He visited Gabon in 2016 and was initiated into Bwiti. In 2018, he helped set up Tabula Rasa Retreat in Portugal, now one of the leading ibogaine treatment facilities globally. He has organized ibogaine conferences in Vienna, Porto and London. He has a PhD in European philosophy from the University of Warwick, UK.

Strictly Confidential

Greg Leavens - CFO

Greg Leavens, CPA CA - a Calgary based financial executive (past CFO and Controller roles) with 30 years experience in public accounting and industry, including the oil & gas exploration / production and service sectors. Greg started his career with KPMG, and has extensive experience in leadership, strategic planning, due diligence reviews, financing, forecasting, financial reporting, treasury and risk management, and regulatory compliance. His background includes significant roles in planning, monitoring, and executing programs to aid in achieving high profitability, growth, and success of results oriented management teams, especially in start-up, entrepreneurial environments.



Richard Avis - COO

Richard Avis is a senior management executive with a 30-year strong background in start-up management and franchising. He most recently operated a Vancouver-based advisory firm specializing in the growth & profitability of franchise operations, including leadership mentoring, brand management and general marketing.



OUR BOARD



Shayne Nyquvest - Chair & Founder

Shayne Nyquvest is the former Executive Vice President of Mackie Research Capital and a founding member of the Canaccord Genuity Group. Nyquvest can personally vouch for the transformational effects of ibogaine and aims to see this treatment adopted by the mainstream medical community as an answer to the opioid epidemic.

Alberto Sola, MD - Co-Founder and President

Clear Sky Addiction Solution's President, Dr Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operations at Clear Sky Recovery. Dr. Sola graduated from Universidad Anahuac. As the Medical Director of Amerimed, he opened four emergency hospitals for tourists in Puerto Vallarta, Cancun, and Cabo San Lucas.




Chief Ian Campbell - Director

Chief Ian Campbell is a hereditary chief of the Squamish Nation located in Vancouver, British Columbia. He has served as an elected member of council since 2005, and was appointed as a Political Spokesperson in 2008. Since 1999 he has been the Cultural Ambassador and Negotiator for the Intergovernmental Relations Department of the Squamish Nation, advancing Aboriginal rights and title, while invigorating substantive economic opportunities through negotiations, collaboration, and partnerships.

Robert Turner - Director

Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants (WMC). His consulting focus is providing guidance to Boards on their governance including proper CEO oversight. Mr. Turner brings experience as a CHRO in both the private and public sectors. Subsequently, he joined Mercer Canada as a Partner focused on consulting within Canadian health care. Robert has served on Universal Ibogaine's Advisory Board since December 2018. Robert has an ICD.D certification from Rotman Business School, an MBA from the Ivey Business School and a BSc (Biochemistry) from the University of Toronto. He serves on the Boards of two other corporations - one private and one not-for-profit.



OUR BOARD (continued)



Shabir Premji - Incoming Director

Shabir Premji is the Chairman and CEO of P Squared Renewables Inc., a TSXV listed company through which Universal Ibogaine will go public. He was Executive Chairman of Alberta Oilsands, a TSXV listed company that raised nearly a \$100 million in the capital markets and successfully found over 300 million barrels of bitumen reserves, merged its Kenya mineral rights in Kenya into Africa Oil Inc., which successfully raised nearly \$1 billion and found major oil reserves in Kenya. He was a Senior Manager with KPMG prior to moving into managing commercial enterprises.

THANK YOU

www.ibogaineinc.com

Contact:
jeremy@ibogaineinc.com

September 14 2020